<DOC>
	<DOCNO>NCT00655837</DOCNO>
	<brief_summary>The purpose study determine safety tolerability combination therapy SGN-40 gemcitabine rituximab treatment lymphoma . This study also intend estimate well disease respond treatment .</brief_summary>
	<brief_title>Trial Define Safety Tolerability SGN-40 , Rituximab , Gemcitabine Patients With DLBCL</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Have histologic diagnosis DLBCL , include transformed histology follicular grade 3 disease . Must least one site biopsyproven disease demonstrate follow : bidimensional measurable disease long axis &gt; = 1.5cm radiographic image positive FDGPET scan baseline . Patients DLBCL either relapse , refractory , progressive disease follow salvage therapy , OR relapse , refractory , progressive disease follow initial therapy medically unfit receive aggressive therapy . Either fresh archived tumor specimen must available . Documented history within 6 month registration cerebral vascular event , unstable angina , myocardial infarction , cardiac symptom . Patients receive allogeneic stem cell transplant . Patients evidence another invasive primary malignancy within past three year nonmelanoma skin cancer , cervical carcinoma situ , situ carcinoma breast , fully resect prostate cancer normal PSA within 8 week registration . Patients active systemic viral , bacterial , fungal infection require intravenous antiinfectives within 4 week prior first dose study drug . Patients history clinical evidence leptomeningeal central nervous system ( CNS ) lymphoma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Antigens , CD40</keyword>
	<keyword>Antibodies , Monoclonal</keyword>
	<keyword>Combined Modality Therapy</keyword>
	<keyword>Lymphoma , Large B-Cell , Diffuse</keyword>
	<keyword>Lymphoma , Non-Hodgkin</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Immunoproliferative Disorders</keyword>
	<keyword>Lymphatic Diseases</keyword>
	<keyword>Lymphoproliferative Disorders</keyword>
	<keyword>Lymphoma</keyword>
</DOC>